Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling

Posted by: | March 12, 2020 | Comments

Gut microbiota could survive in the hypoxic TME and prolong mouse survival: Representative image of HIF1α stain of different volumes of tumors. Immunofluorescence analysis of hypoxia: HIF1α (green) expression on different-volume tumor tissue slides.

Most studies focus on how intestinal microbiota influence cancer immunotherapy through activating gut immunity. However, immunotherapies related to innate responses such as CD47 blockade rely on the rapid immune responses within the tumor microenvironment. Using one defined anaerobic gut microbiota to track whether microbiota interact with host immunity, we observed that Bifidobacterium facilitates local anti-CD47 immunotherapy on tumor tissues through the capacity to accumulate within the tumor microenvironment. Systemic administration of Bifidobacterium leads to its accumulation within the tumor and converts the nonresponder mice into responders to anti-CD47 immunotherapy in a stimulator of interferon genes (STING)– and interferon-dependent fashion. Local delivery of Bifidobacterium potently stimulates STING signaling and increases cross-priming of dendritic cells after anti-CD47 treatment. Our study identifies the mechanism by which gut microbiota preferentially colonize in tumor sites and facilitate immunotherapy via STING signaling.

Read more: Rockefeller University Press

Yaoyao Shi, Wenxin Zheng, Kaiting Yang, Katharine G. Harris, Kaiyuan Ni, Lai Xue, Wenbin Lin, Eugene B. Chang, Ralph R. Weichselbaum, and Yang-Xin Fu. J Exp Med. DOI: https://doi.org/10.1084/jem.20192282. 06 March 2020.





Stay up-to-date!
Email Address *
First Name
Last Name

* indicates required
Privacy Policy




Terms & Conditions | Privacy Policy | © 2020 The Translational Microbiome Research Forum